Topic
Cancer Research UK’s Centre for Drug Development is using TrialAssure LINK AI to support medical writing in CRUK-sponsored studies LONDON (June 18, 2026) – TrialAssure, a leading technology provider…
Artificial intelligence (AI) continues to create new possibilities across life sciences, and few areas make that clearer than drug discovery. At the recent MichBio 2026 Michigan Drug Discovery…
Artificial intelligence (AI) is rapidly changing the way clinical and regulatory content is developed across the pharmaceutical and biotechnology industry. The AI medical writing market alone is expected…
ANN ARBOR, Mich. (May 04, 2026) — TrialAssure, an award-winning global provider advancing clinical trial transparency, disclosure, and data sharing, announced today that Zach Weingarden, Director of AI Technology and Applications, has been named a 2026…
BOSTON (March 3, 2026) — TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, announced today announced the launch of its AI in Medical…
AUSTIN, Texas. (February 24, 2026) — TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, announced today its expanded role at the upcoming PHUSE…
In a recent joint session hosted by TrialAssure and MMS, medical writing professionals from the US and UK gathered to explore one of the most talked-about topics in…
CANTON, Mich. (December 2, 2025) – TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, announced today that Chris Hurley, MBA, Americas Director for…
Every submission tells a story, but Development Safety Update Reports (DSURs) require a special kind of narrative. They blend clinical development history, emerging safety data, and a forward-looking…
The integration of artificial intelligence (AI) into pharmaceutical and biotechnology workflows has accelerated significantly in recent years. According to peer-reviewed research by the Tufts Center for the Study…
